TEL AVIV (Reuters) - Israeli biotechnology firm Atox Bio, developing a drug it hopes can treat severe infections such as those caused by flesh-eating bacteria and deadly viruses, expects to ask investors for more money this year to fund extended phase II trials.
via Reuters: Health News Read More Here..
No comments:
Post a Comment